Institutional projects At VHIR, we promote institutional projects that consolidate our mission as a leading biomedical research center. These projects, often wide in scope and with strong cross-cutting involvement, align with shared objectives alongside public and private institutions to strengthen research, innovation, and knowledge transfer within the healthcare system. Through structured collaboration with public administrations, funding bodies, and regulatory agencies, we work to generate a transformative and sustainable impact that reinforces the integration of science, health, and society. TACTIC: Precision Diagnosis and Innovative Therapies TACTIC is a project of the Accredited Health Research Institute, Institut de Recerca – Vall d’Hebron University Hospital (IR-HUVH), that addresses the strategic health challenges posed by non-communicable and rare diseases, with the aim of strengthening research based on systems medicine. The goal is to develop new perspectives for personalized and precision medicine in the fields of cancer, cardiovascular and neurological disorders, and rare diseases, from childhood through to adulthood. Vall d’Hebron strengthens the development of advanced therapies with the CERTERA project Vall d’Hebron participates in the national consortium CERTERA, receiving €2.6 million from the Carlos III Health Institute. The project will promote the development of advanced therapies, such as those based on TIL and CAR-T, led by VHIO, as well as the production of viral and non-viral vectors, led by VHIR. Cutting-edge infrastructures will be created for clinical trials and technology transfer, strengthening scientific competitiveness in the field of advanced therapies. BRIDGE: A commitment to a more digital, collaborative, and inclusive future in paediatric clinical trials VHIR's BRIDGE project promotes a novel decentralized model for pediatric clinical trials. Funded by the Carlos III Health Institute and the EU – NextGenerationEU, it seeks to guarantee access to innovative therapies for all children, regardless of their place of residence or socioeconomic status, by improving the capacity, inclusivity, and interoperability of clinical trials.
